Autosomal Dominant Optic Atrophy Plus (ADOA+)

Autosomal Dominant Optic Atrophy Plus (ADOA+) is a rare, inherited condition in which the optic nerves (the “cables” that carry visual signals from the eyes to the brain) slowly degenerate. People first notice blurry central vision and trouble with color vision in childhood. Later, some develop extra problems outside the eyes—such as hearing loss, balance trouble, numbness or weakness in the legs and feet, problems with eye movements, or muscle fatigue. Most families with ADOA+ have a harmful change (variant) in a gene called OPA1, which is important for healthy mitochondria—the tiny “power plants” inside our cells. When OPA1 does not work properly, nerve cells that need a lot of energy (like retinal ganglion cells in the optic nerve and long peripheral nerves) are especially vulnerable. BioMed Central+2NCBI+2

Autosomal dominant optic atrophy plus (ADOA-plus) is a rare inherited condition where the optic nerves slowly get weaker, causing blurred central vision, pale optic nerves, and color-vision problems, usually beginning in childhood. “Plus” means the disease also affects other body systems—commonly balance and walking (ataxia), hearing (sensorineural hearing loss), eye movements (chronic progressive external ophthalmoplegia—CPEO), muscles (myopathy), and nerves in the feet and hands (peripheral neuropathy). Most cases happen because of harmful changes in a nuclear gene called OPA1, which helps mitochondria (the cell’s energy factories) fuse and work properly. When OPA1 does not work, mitochondria become fragmented, energy production falls, and retinal ganglion cells (and other energy-hungry cells) are damaged over time. There is no FDA-approved cure yet; care focuses on vision rehab and whole-body support while research explores antioxidants, mitochondrial-targeted drugs, and gene-based therapies. PMC+3MDPI+3PMC+3

Classic (eye-only) dominant optic atrophy affects at least about 1 in 35,000 people; a subset (around 20%) have the “plus” form with extra-ocular features. PMC+1

OPA1 helps mitochondria keep their normal shape (fusion), maintain inner-membrane “cristae,” and control cell survival. OPA1 variants disturb these jobs. This leads to energy shortage, more oxidative stress, and gradual loss of retinal ganglion cells and other nerves. Some OPA1 variants act by “haploinsufficiency” (not enough working protein), while others have dominant-negative effects; both can lead to ADOA or ADOA+. EyeWiki+2PMC+2

Other names

ADOA+ is also called “Dominant Optic Atrophy Plus,” “DOA+,” or “OPA1-related optic atrophy with extra-ocular features.” Classic dominant optic atrophy (without “plus”) is sometimes called “Kjer disease,” but “Kjer disease” usually refers to the eye-only form. BioMed Central+1

Types

1. Eye-only (classic) dominant optic atrophy. Progressive, bilateral central vision loss and color vision problems from childhood, without consistent extra-ocular signs. This is the baseline OPA1 phenotype. BioMed Central+1
2. ADOA+ (eye plus systemic features). Eye findings plus one or more of: sensorineural hearing loss, ataxia, peripheral neuropathy (numbness, tingling, weakness), myopathy, chronic progressive external ophthalmoplegia (CPEO; limited eye movements), spasticity, or rarely a multiple-sclerosis-like illness. The extra features often appear in adolescence or adulthood after the eye symptoms. PMC+1
3. Severe or complex OPA1-related disease (rare). Very uncommon families or individuals (including some with two OPA1 variants) can show broader neurodegeneration beyond typical ADOA+. This is unusual but reported. BioMed Central

Causes

In ADOA+, the “root cause” is almost always a pathogenic variant in OPA1. Below are 20 practical “causes and contributors”—genetic mechanisms and biological/clinical factors—that explain why the disease appears and why it can look worse in some people.

1. OPA1 loss-of-function variants (haploinsufficiency). One broken copy of OPA1 makes too little working protein, weakening mitochondrial fusion and inner-membrane structure in retinal ganglion cells. EyeWiki

2. Dominant-negative OPA1 missense variants. Some missense changes produce an abnormal OPA1 protein that interferes with the normal one, increasing cell stress and nerve loss. PMC

3. GTPase-domain defects. The GTPase portion of OPA1 powers membrane remodeling; changes here strongly affect function and can push toward ADOA+. PMC+1

4. BSE-domain defects. Newer work shows unique roles of the BSE domain in apoptosis control and mitochondrial integrity; variants here can worsen disease. BioMed Central

5. Cristae disorganization. OPA1 keeps inner-membrane folds stable; when disrupted, energy production suffers and retinal ganglion cells degenerate. EyeWiki

6. Impaired mitochondrial fusion. Without normal fusion, damaged mitochondria accumulate, raising oxidative stress and triggering cell death. EyeWiki

7. Increased reactive oxygen species (ROS). OPA1 defects raise oxidative stress, which particularly harms long, energy-hungry neurons. EyeWiki

8. Greater susceptibility to apoptosis. Stress signaling tilts toward programmed cell death in OPA1-mutant cells, thinning the optic nerve. PMC

9. Mitochondrial DNA (mtDNA) instability/multiple deletions (in some). OPA1 dysfunction can secondarily disturb mtDNA maintenance, compounding nerve injury. PMC

10. Axonal transport strain in long neurons. Peripheral nerves and optic nerve fibers are long and metabolically demanding; OPA1 defects make them vulnerable. BioMed Central

11. High-metabolic-demand tissues (selective vulnerability). Retinal ganglion cells and auditory neurons require sustained ATP; energy shortfall promotes loss. BioMed Central

12. Age-related accumulation of mitochondrial damage. Over time, imperfect repair worsens energy failure, so “plus” signs may emerge later. BioMed Central

13. Fever or systemic illness stressors. Mitochondrial disease often worsens during illness; vulnerability can unmask neuropathy or fatigue. (General mitochondrial principle applied to ADOA+.) BioMed Central

14. Ototoxic drugs (e.g., aminoglycosides) as modifiers of hearing. People with mitochondrial vulnerability may be more sensitive to known ototoxins. (Clinical caution consistent with mitochondrial disorders.) BioMed Central

15. Smoking and alcohol as oxidative stressors. These can add oxidative stress and may speed nerve damage in mitochondrial disease. (General mitochondrial/optic neuropathy guidance.) BioMed Central

16. Poor nutrition (e.g., B12 deficiency) worsening neuropathy. Independent, treatable causes of neuropathy can compound OPA1-related nerve dysfunction. BioMed Central

17. Coexisting endocrine or metabolic stress (e.g., diabetes). Diabetes neuropathy can add to OPA1-related neuropathy and balance problems. BioMed Central

18. Head trauma or repetitive vibration exposure. Axonal injury on a background of mitochondrial fragility may aggravate symptoms. BioMed Central

19. Genetic background (modifiers). Other genes can shape severity, explaining differences within families even with the same OPA1 variant. PubMed

20. Environmental heat/stress intolerance. Neurons with poor energy reserve perform worse under heat or exertion, revealing subtle deficits. BioMed Central

Symptoms

1. Blurry central vision that gradually worsens from childhood; reading small print becomes hard. Peripheral vision is usually less affected early on. BioMed Central

2. Color vision problems (especially blue-yellow or red-green) due to retinal ganglion cell dysfunction. BioMed Central

3. Central scotoma (a “hole” or dim spot in the center of vision) found on field testing. ADOA

4. Reduced visual acuity in both eyes, often symmetric; severity varies widely even within the same family. MedlinePlus

5. Optic disc pallor (pale appearance of the optic nerve head) seen by the eye doctor. EyeWiki

6. Sensorineural hearing loss that may appear in the teens or adulthood; sometimes it’s subtle at first (struggling in noisy rooms). PMC+1

7. Peripheral neuropathy with numbness, tingling, burning pain, or weakness in the feet and hands due to axonal loss. PMC

8. Ataxia—unsteady walking and poor balance from nerve and cerebellar involvement. PMC

9. Myopathy—muscle fatigue or aching with activity; sometimes mild elevation of creatine kinase. PMC

10. Chronic progressive external ophthalmoplegia (CPEO)—stiff, limited eye movements; sometimes droopy eyelids (ptosis). PMC

11. Spasticity or pyramidal signs (stiffness, brisk reflexes) in a minority of cases. PMC

12. MS-like episodes (rare) with neurologic symptoms that mimic multiple sclerosis. PMC

13. Glare sensitivity and poor night vision because damaged ganglion pathways reduce visual reserve under stress. BioMed Central

14. Fatigue and exercise intolerance from broader mitochondrial energy shortage. BioMed Central

15. Psychosocial stress and anxiety related to progressive vision and hearing challenges, work limitations, and driving restrictions. stoketherapeutics.com

Diagnostic tests

A) Physical examination (bedside/clinic)

1. Neuro-ophthalmologic exam. An eye doctor checks visual acuity, pupils, color vision, and the optic nerve appearance. The optic discs often look pale (temporal pallor). EyeWiki

2. Visual field testing (confrontation at bedside). A quick screen can detect central field loss before formal perimetry is done. ADOA

3. General neurologic exam. Reflexes, tone, vibration sense, and coordination are checked to look for neuropathy, pyramidal signs, or ataxia in ADOA+. PMC

4. Gait and balance tests (Romberg, tandem walk). Simple clinic maneuvers can reveal sensory ataxia or cerebellar signs linked to “plus” features. PMC

5. Bedside hearing checks (voice, tuning fork). Rinne and Weber tests can suggest sensorineural hearing loss before formal audiology. Orpha

B) Manual/functional vision tests

6. Best-corrected visual acuity (ETDRS/Snellen). Quantifies central vision loss and tracks changes over time. BioMed Central

7. Color vision testing (Ishihara or Farnsworth). Detects the common color vision defects seen in ADOA. BioMed Central

8. Amsler grid. A quick tool that can show a central scotoma or distortion noticed by the patient at home. ADOA

9. Automated perimetry (e.g., Humphrey 24-2). Maps the visual field and typically shows a central or cecocentral scotoma pattern. BioMed Central

10. Contrast sensitivity testing. Helps explain complaints of “washed-out” or low-contrast vision beyond standard acuity. BioMed Central

C) Laboratory and pathological (including genetics)

11. OPA1 genetic testing (primary test). Confirms the diagnosis and allows family counseling; most ADOA/ADOA+ cases carry a heterozygous OPA1 variant. PubMed

12. Targeted mitochondrial panels / exome sequencing (if OPA1 testing is negative). Looks for rare non-OPA1 causes of optic neuropathy plus syndromes. BioMed Central

13. mtDNA deletion/instability assessment (select cases). Secondary multiple mtDNA deletions may be present and can explain severe plus features. PMC

14. Metabolic labs (CK, lactate) and B-vitamins. CK may be mildly elevated with myopathy; B12 deficiency or other treatable factors can worsen neuropathy. PMC

15. Glucose/HbA1c and thyroid tests. Diabetes or thyroid disease can aggravate neuropathy and fatigue and should be ruled out or treated. BioMed Central

D) Electrodiagnostic and audiologic

16. Pattern visual evoked potentials (VEP). Often show delayed/low amplitudes reflecting optic nerve conduction problems. BioMed Central

17. Electroretinography (ERG, especially pattern ERG). Helps separate retinal from optic nerve dysfunction; ganglion-cell dysfunction can reduce pattern ERG. BioMed Central

18. Nerve conduction studies/electromyography (NCS/EMG). In ADOA+, studies may show an axonal sensorimotor polyneuropathy when neuropathy symptoms are present. PMC

19. Pure-tone audiometry and speech testing. Quantifies sensorineural hearing loss; serial testing tracks progression and guides hearing support. Orpha

20. Auditory brainstem response (ABR). Useful when standard audiometry is difficult; can detect auditory pathway dysfunction consistent with ADOA+ hearing loss. Orpha

E) Imaging

(These studies are commonly used alongside the tests above.)

1. Optical coherence tomography (OCT) of the retinal nerve fiber layer (RNFL) and ganglion cell complex. Typically shows thinning that correlates with vision loss. BioMed Central

2. Fundus photography. Documents optic disc pallor and helps monitor change over time. EyeWiki

3. MRI of brain and orbits (with contrast). Recommended to exclude other causes of optic neuropathy (compression, inflammation) that could be treatable and to evaluate “plus” neurologic signs. Gene Vision

4. Inner ear/temporal bone imaging (selected cases). Considered when planning cochlear implantation or when other ear conditions are suspected. Orpha

Non-pharmacological treatments (therapies & others)

1. Low-vision rehabilitation – A structured program teaches new reading strategies, optimal lighting, contrast enhancement, and device use (magnifiers, electronic readers). Purpose: keep you independent at school/work/home. Mechanism: replaces lost central fixation with alternative strategies and devices to maximize remaining vision. AOA+1

2. Assistive technology – screen readers, high-contrast modes, large-print settings, voice assistants, OCR apps. Purpose: make information accessible. Mechanism: converts text to speech and enlarges/clarifies content to bypass central scotoma. AOA

3. Orientation & mobility training – cane skills, safe street crossing, route planning. Purpose: safe movement and confidence outdoors. Mechanism: systematic mobility techniques compensate for reduced central vision. AOA

4. Tinted lenses/filters – tailored tints for glare, contrast, and color-vision support. Purpose: reduce light sensitivity and improve function. Mechanism: filters specific wavelengths and boosts contrast detection. EyeWiki

5. Audiology care & hearing aids – early fitting of modern hearing aids. Purpose: improve speech understanding, reduce listening fatigue. Mechanism: amplifies and clarifies frequencies you cannot hear well. Adult Hearing

6. Cochlear implant evaluation (if hearing is severe-to-profound) – consider when hearing aids no longer help. Purpose: restore access to speech sounds. Mechanism: an implant stimulates the auditory nerve directly. American Academy of Audiology+1

7. Physical therapy (PT) – balance, gait, and strength training. Purpose: reduce falls and improve endurance. Mechanism: neuroplasticity and muscle conditioning compensate for ataxia and weakness. umdf.org

8. Occupational therapy (OT) – home/work adaptations and energy-saving routines. Purpose: make daily tasks safer and easier. Mechanism: task modification + adaptive equipment reduce energy cost and risk. umdf.org

9. Speech-language therapy (selected) – for dysarthria/swallow strategies if bulbar muscles are involved. Purpose: clearer communication and safer swallowing. Mechanism: targeted muscle practice and compensatory techniques. umdf.org

10. Exercise program (graded, supervised) – walking, cycling, resistance. Purpose: improve stamina without over-exertion. Mechanism: improves mitochondrial biogenesis and muscle efficiency when paced. umdf.org

11. Sleep optimization – consistent sleep schedule and management of apnea/insomnia. Purpose: reduce daytime fatigue and brain fog. Mechanism: restores energy balance and cognitive function. umdf.org

12. Illness-prevention plan – vaccines, early infection treatment, hydration during fever. Purpose: avoid mitochondrial decompensation during illness. Mechanism: reduces metabolic stress spikes that worsen symptoms. umdf.org

13. Medication review – avoid or limit drugs that may stress mitochondria when possible. Purpose: reduce avoidable worsening. Mechanism: removes energy-toxic exposures. umdf.org

14. Nutrition counseling – regular meals, balanced macros, adequate protein, hydration. Purpose: steady fuel for cells. Mechanism: supports ATP production and avoids prolonged fasting. kennedykrieger.org

15. Psychological support – counseling or peer groups. Purpose: build coping skills and treat depression/anxiety linked to vision/hearing loss. Mechanism: evidence-based therapy improves quality of life and adherence. umdf.org

16. Workplace/school accommodations – extra time, accessible materials, seating. Purpose: maintain performance. Mechanism: environmental changes reduce visual/hearing load. lhon

17. Driving assessment & alternatives – formal low-vision driving eval where legal; mobility planning if driving not safe. Purpose: safety. Mechanism: objective testing + transport planning. AOA

18. Falls-prevention home changes – grab bars, high-contrast steps, non-slip floors. Purpose: prevent injury with ataxia/neuropathy. Mechanism: hazard reduction and visual cues. umdf.org

19. Headache management (non-drug first) – hydration, trigger tracking, blue-light hygiene. Purpose: reduce migraine-like episodes. Mechanism: lifestyle stabilization. BioMed Central

20. Clinical-trial engagement – discuss trials (e.g., idebenone, OPA1-targeted or gene approaches). Purpose: access emerging options. Mechanism: investigational therapies under oversight. PMC+1

---

Drug treatments

Reality check: There are no FDA-approved drugs specifically for ADOA/ADOA-plus. Medicines are used off-label to manage symptoms (neuropathy pain, spasticity, mood, migraine, etc.). Below are examples with links to their FDA labels where available; dosing MUST be individualized by your clinician based on your age, weight, kidney/liver function, comorbidities, and other meds.

1. Gabapentin (neuropathic pain). Class: anticonvulsant/neuropathic agent. Typical dosing: titrated from 300 mg/day to divided doses; renal dosing required. When: daily. Purpose: reduce burning/tingling pain. Mechanism: binds α2δ subunit of voltage-gated calcium channels to reduce excitatory transmitters. Key side effects: sedation, dizziness; watch for respiratory depression with CNS depressants. FDA label: NEURONTIN/GRALISE. FDA Access Data+2FDA Access Data+2

2. Duloxetine (neuropathic pain, depression/anxiety). Class: SNRI. Typical dosing: 30–60 mg/day; avoid MAOIs. When: daily. Purpose: nerve pain relief and mood support. Mechanism: boosts serotonin/norepinephrine in descending pain pathways. Side effects: nausea, dry mouth, BP changes, serotonin syndrome risk. FDA label (Cymbalta/Drizalma): FDA Access Data+2FDA Access Data+2

3. Baclofen (spasticity/cramps). Class: GABA-B agonist. Dose: start low (5 mg) and titrate; taper slowly to avoid withdrawal. When: 2–3× daily (or long-acting granules/solution). Purpose: reduce painful spasm. Mechanism: spinal inhibition of reflex arcs. Side effects: drowsiness, weakness; dose-adjust in renal impairment. FDA labels (Lyvispah, Ozobax, Fleqsuvy): FDA Access Data+2FDA Access Data+2

4. Acetazolamide (selected migraine-like or episodic symptoms; sometimes used in channelopathies). Class: carbonic anhydrase inhibitor. Dose: varies; tablets 125–250 mg; specialist discretion. Purpose/Mechanism: mild carbonic anhydrase inhibition that can affect neuronal excitability and CSF dynamics; used case-by-case. Side effects: paresthesia, kidney stones, electrolyte changes. FDA label (Diamox): FDA Access Data+1

5. Pregabalin (neuropathic pain, anxiety). Class: α2δ ligand. Dose: individualized; renal dosing. Purpose/Mechanism: similar to gabapentinoids. Side effects: edema, dizziness. FDA background (class): see gabapentinoid labels as reference; clinician-directed. FDA Access Data

6. Amitriptyline (sleep/neuropathic pain; low dose at night). Class: TCA. Dose: often 10–25 mg hs to start. Mechanism: serotonin/norepinephrine reuptake blockade; anticholinergic. Risks: anticholinergic effects, QTc—specialist oversight; use FDA labeling for TCAs. (General pharmacologic class guidance via FDA labels; clinician selects exact brand/label.) FDA Access Data

7. Topiramate (migraine prevention if needed). Class: anticonvulsant. Mechanism: multiple (Na+ channels, GABA, glutamate). Side effects: paresthesia, cognitive fog, weight loss; avoid in kidney stones risk. (Use FDA label for topiramate for precise dosing.) FDA Access Data

8. Sertraline/SSRIs (depression/anxiety common in chronic vision/hearing loss). Class: SSRI. Mechanism: serotonin reuptake inhibition. Side effects: GI upset, sexual dysfunction, hyponatremia; check drug–drug interactions. (Dose per FDA label.) FDA Access Data

9. Modafinil (daytime sleepiness/fatigue in selected cases). Class: wakefulness agent. Mechanism: promotes cortical arousal (exact mechanism complex). Risks: insomnia, anxiety; interactions. (Dose per FDA label.) FDA Access Data

10. Riboflavin (vitamin B2) high-dose is often used as a supplement rather than Rx drug for mitochondrial disorders and migraine prevention; clinicians sometimes prescribe medical-grade products. Note: dietary supplement status means no FDA drug label; evidence base is mixed. Office of Dietary Supplements

11. Coenzyme Q10 (ubiquinone/ubiquinol) – usually a supplement, not an FDA-approved drug; used widely in mitochondrial clinics to support electron transport. Evidence suggests possible benefit in mitochondrial disorders, but responses vary. (See supplement section below.) Office of Dietary Supplements+1

12. Idebenone – a short-chain CoQ10 analogue. Important: Not FDA-approved in the U.S.; has orphan designations and approvals elsewhere for LHON, and small OPA1-DOA studies suggest potential benefit, but use is off-label/experimental in ADOA. Clinicians may discuss risks/costs. Wiley Online Library+3FDA Access Data+3FDA Access Data+3

---

Dietary molecular supplements

1. Coenzyme Q10 (ubiquinone/ubiquinol) – 100–300 mg/day in divided doses with fat. Function: electron carrier in complex I/II → III. Mechanism: supports ATP and reduces oxidative stress; best data among supplements for mitochondrial disorders. NCBI+1

2. Riboflavin (Vitamin B2) – 100–400 mg/day (specialist guided). Function: cofactor for flavoproteins (complex I/II). Mechanism: improves electron transport and may help migraine. Office of Dietary Supplements

3. Alpha-lipoic acid – commonly 300–600 mg/day. Function: antioxidant and mitochondrial cofactor. Mechanism: reduces ROS and may support energy enzymes. umdf.org

4. Acetyl-L-carnitine / L-carnitine – individualized dosing. Function: shuttles fatty acids into mitochondria. Mechanism: supports energy transfer; may reduce fatigue/muscle pain in some. mitocanada.org

5. Creatine monohydrate – 2–5 g/day. Function: energy buffer (PCr system). Mechanism: boosts quick ATP availability for muscle. mitocanada.org

6. Vitamin C & E – antioxidant support. Mechanism: reduces oxidative stress; often used with CoQ10. mitocanada.org

7. Selenium – low-dose under supervision. Mechanism: part of glutathione peroxidase; sometimes combined with CoQ10. MDPI

8. Arginine/Citrulline – used mainly in MELAS for NO pathway; in ADOA-plus may be considered case-by-case by mitochondrial specialists. Mechanism: NO donor, vasodilatory support. ScienceDirect

9. N-acetylcysteine (NAC) – antioxidant precursor to glutathione. Mechanism: replenishes antioxidant defenses during oxidative stress. kennedykrieger.org

10. Vitamin D – bone/muscle support and general health; replete deficiency. Mechanism: supports neuromuscular function and immune health. umdf.org

---

Immunity boosters, regenerative, and stem-cell drugs

There are no FDA-approved immunity-booster, regenerative, or stem-cell drugs for ADOA/ADOA-plus. The FDA repeatedly warns patients about clinics selling unapproved stem-cell/exosome products for many diseases; these products can be dangerous and are illegal without FDA approval. Gene/stem-cell therapies should only be received inside regulated clinical trials. U.S. Food and Drug Administration+3U.S. Food and Drug Administration+3U.S. Food and Drug Administration+3

---

Surgeries

1. Cochlear implant (for severe-to-profound sensorineural hearing loss) – an electronic device placed in the inner ear to stimulate the auditory nerve. Why: when properly-fitted hearing aids no longer give useful speech understanding. Evidence/guidelines: adult candidacy and pathways are well defined. American Academy of Audiology+1

2. Ptosis surgery (levator resection or frontalis sling) for CPEO-related droopy eyelids that block vision. Why: to open the visual axis and reduce chin-up posture; must avoid over-correction to prevent exposure keratopathy. EyeWiki+1

3. Strabismus surgery (selected CPEO patients with stable double vision). Why: align eyes to improve comfort; outcomes differ due to myopathic muscles, and resections can be more helpful than recessions in CPEO. PubMed+1

4. Implantable bone-anchored hearing solutions (if mixed hearing loss or chronic ear disease prevents hearing-aid use). Why: improve sound transmission via bone conduction; candidacy is specialist-determined. MDPI

5. Low-vision surgical adjuncts are limited; most visual help comes from rehabilitation and devices, not eye surgery, because optic-nerve damage cannot be surgically reversed. PMC

---

Preventions

1. Keep vaccinations current and treat infections early to limit metabolic stress. umdf.org

2. Avoid prolonged fasting/dehydration; eat regularly during illness. kennedykrieger.org

3. Pace activity (rest between tasks) to avoid post-exertional crashes. umdf.org

4. Review medications that may worsen mitochondrial function; use safer alternatives when possible. umdf.org

5. Protect hearing (limit loud noise; use protection). Adult Hearing

6. Use good lighting and high-contrast markings at home to prevent falls. AOA

7. Manage migraines/headaches with lifestyle steps and medical plans when needed. BioMed Central

8. Sleep well and treat sleep disorders. umdf.org

9. Stay physically active with a tailored, graded program. umdf.org

10. Engage early with low-vision and audiology services; earlier adaptation works better. AOA

---

When to see doctors

• New or worsening vision loss, color-vision change, or central blur. Nature

• New double vision, droopy eyelid blocking sight, or eye-movement limits. EyeWiki

• Hearing that suddenly declines or hearing aids stop helping—ask about CI referral. American Academy of Audiology

• New falls, numbness/burning pain, or severe fatigue limiting daily life. umdf.org

• Depression/anxiety or sleep problems interfering with function. umdf.org

• Interest in clinical trials for mitochondrial or OPA1 therapies. PMC

---

What to eat / what to avoid

• Eat regularly (don’t skip meals), with balanced carbs, proteins, and healthy fats. kennedykrieger.org

• Stay hydrated, more during illness/heat. kennedykrieger.org

• Adequate protein to support muscle repair. umdf.org

• Colorful fruits/vegetables for antioxidants (vitamins C/E, carotenoids). mitocanada.org

• Consider clinician-guided supplements (CoQ10, riboflavin, carnitine, creatine) if appropriate. Office of Dietary Supplements

• Limit alcohol (can worsen neuropathy and sleep). umdf.org

• Avoid crash diets/long fasts that deplete energy. kennedykrieger.org

• Caution with ultra-processed foods that spike/valley energy. umdf.org

• If lactose/gluten trigger IBS-like symptoms, discuss with your clinician; gut distress can worsen fatigue. umdf.org

• During fever or surgery, use a plan for extra fluids, calories, and medicines to reduce metabolic stress. umdf.org

---

Frequently Asked Questions

1) Is ADOA-plus the same as simple ADOA?
No. ADOA affects mostly the optic nerves; ADOA-plus adds hearing, balance, muscle, nerve, and eye-movement problems. Both most often involve OPA1 variants. Orpha

2) How common is it?
ADOA is the most common inherited optic neuropathy; estimates range roughly 1:12,000–1:50,000. ADOA-plus makes up about 10–20% of those with OPA1 changes. EyeWiki+1

3) What age does it start?
Usually in childhood or teenage years, but adult-onset can occur. Nature

4) Can glasses or cataract surgery fix it?
No. The problem is the optic nerve, not the lens. Low-vision rehab and assistive devices are the main visual supports. AOA

5) Is there a cure or FDA-approved drug?
Not yet. Studies test compounds like idebenone and mitochondrial-targeted approaches, but idebenone is not FDA-approved in the U.S. for ADOA/ADOA-plus. PMC+1

6) Does idebenone help?
Small studies in OPA1-DOA show modest stabilization or improvement for some patients; evidence remains limited, and access varies by country. Discuss risks/costs with your specialist. Wiley Online Library+1

7) Are there lifestyle steps that really matter?
Yes—regular meals, hydration, graded exercise, sleep care, infection prevention, and early rehab/audiology support. kennedykrieger.org+1

8) Should I take CoQ10 or riboflavin?
Many mitochondrial clinics try them; responses vary. These are supplements, not FDA-approved drugs; discuss dose/quality with your clinician. Office of Dietary Supplements+1

9) Will I lose all vision?
Most people keep some peripheral vision; central vision and color are mainly affected. Early rehab helps you adapt. Nature+1

10) What about hearing?
If hearing aids are not enough, cochlear implant evaluation is reasonable under modern guidelines. American Academy of Audiology

11) Is surgery available for the eyes?
Surgery can lift severe ptosis or treat certain strabismus in CPEO, but it cannot repair the optic nerve. EyeWiki+1

12) Are stem-cell treatments available?
No approved stem-cell/exosome treatments for this disease; be cautious of unapproved clinics. U.S. Food and Drug Administration+1

13) Can family members be tested?
Yes. Genetic counseling and testing for relatives at risk is standard. MDPI

14) Are there research trials I can join?
Trials in hereditary optic neuropathies and OPA1 disease appear periodically; ask your specialists and patient groups. PMC+1

15) Where can I learn more in patient-friendly language?
Patient organizations for ADOA publish updates on treatments and coping tools. ADOA

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 04, 2025.